{"product_id":"livanova-business-model-canvas","title":"LivaNova Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas for a high-value medical-device company: strategic snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind LivaNova with a concise Business Model Canvas that maps value propositions, key partnerships, and revenue drivers. This snapshot reveals how the company competes in high-value medical-device markets and where growth levers lie. For a section-by-section, editable Word and Excel version with actionable insights, purchase the full Business Model Canvas today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTertiary hospitals and surgical centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with tertiary hospitals and surgical centers enables co-development of clinical workflows and collection of real-world evidence for cardiopulmonary and neuromodulation therapies, supplying sites for clinical trials and hands-on surgeon training.\u003c\/p\u003e\n\u003cp\u003eThese centers serve as reference accounts that accelerate adoption in new geographies and support health-economic studies to demonstrate cost-effectiveness to payers and hospital systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and research institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with academic and research institutions accelerates development of novel biomaterials, device algorithms and stimulation protocols through shared expertise and co-development projects. Access to leading investigators and NIH-funded programs (NIH FY2024 budget $49.5B) strengthens study design, publication and clinical trial pipelines. Shared preclinical facilities cut translational timelines and allow securing early IP options on breakthrough technologies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulators and notified bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngage proactively with FDA (use the Q-Submission program) and with EU notified bodies under EU MDR, effective 26 May 2021, to align pivotal trial endpoints and post-market commitments. Maintain routine quality system audits and vigilance reporting to meet regulatory requirements and support CE marking and PMA\/510(k) pathways. Leverage pre-submission guidance to shorten time-to-market and de-risk regulatory review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic suppliers and manufacturing partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic suppliers and manufacturing partners secure continuity for pumps, sensors and biocompatible polymers, supporting LivaNova’s FY2024 revenue of about $1.03 billion by protecting critical supply lines.\u003c\/p\u003e\n\u003cp\u003eCo-engineering reduces COGS and improves reliability through joint design-for-manufacture efforts, while qualifying dual sources mitigates single‑supplier risk.\u003c\/p\u003e\n\u003cp\u003ePartners must scale capacity ±20–30% for procedure seasonality and new product launches to avoid stockouts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003edual‑sourcing\u003c\/li\u003e\n\u003cli\u003eco‑engineering\u003c\/li\u003e\n\u003cli\u003e±20–30% scaling\u003c\/li\u003e\n\u003cli\u003eprotect pumps\/sensors\/polymers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and health technology assessors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner with payers and HTA bodies to secure reimbursement pathways for neuromodulation and surgical devices, providing outcomes and budget-impact dossiers to support coverage; in 2024 payers intensified real-world evidence requirements for device reimbursement. Pilot value-based agreements where feasible to align payment with outcomes and expand coverage indications to grow addressable markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 trend: increased RWE demand by payers\u003c\/li\u003e\n\u003cli\u003eDeliver outcomes and budget-impact dossiers\u003c\/li\u003e\n\u003cli\u003ePilot value-based agreements\u003c\/li\u003e\n\u003cli\u003eExpand coverage indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, academia and suppliers accelerate biomaterials, trials and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTertiary hospitals enable co-development, trials and surgeon training, accelerating adoption across geographies.\u003c\/p\u003e\n\u003cp\u003eAcademic partners speed biomaterials and algorithm R\u0026amp;D; NIH FY2024 budget $49.5B supports trial pipelines.\u003c\/p\u003e\n\u003cp\u003eStrategic suppliers secure pumps\/sensors\/polymers, dual‑sourcing and co‑engineering cut COGS; LivaNova FY2024 revenue ~$1.03B.\u003c\/p\u003e\n\u003cp\u003ePayers demand more RWE in 2024; value-based pilots and HTA dossiers expand reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eTrial sites\/reference accounts\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003eNIH budget\u003c\/td\u003e\n\u003ctd\u003e$49.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eRevenue protection\u003c\/td\u003e\n\u003ctd\u003e$1.03B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eRWE demand\u003c\/td\u003e\n\u003ctd\u003eIncreased\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for LivaNova detailing its nine blocks—customer segments (cardiac, neuromodulation, hospitals), value propositions, channels, key partners, revenue streams and cost structure. Includes competitive advantages and SWOT-linked insights for strategy, funding or presentation use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of LivaNova’s business model with editable cells, quickly identifying core components to relieve stakeholder misalignment and streamline strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapy-focused R\u0026amp;D and clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign next-gen heart-lung systems, oxygenators and neuromodulation devices with focused R\u0026amp;D and engineering, targeting reduced priming volumes and improved biocompatibility. Run feasibility through pivotal trials typically enrolling 200–800 patients over 12–36 months to prove safety and efficacy. Generate robust evidence for new indications and labeling to satisfy FDA\/CE requirements. Iterate product cycles quarterly based on clinician feedback and outcomes data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, quality, and compliance operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintain ISO 13485-compliant QMS across 10 global sites, supporting LivaNova’s 2024 operations and ~$1.0B revenue scale; prepare regulatory submissions, respond to queries, and manage audits with documented timelines. Conduct continuous post-market surveillance and risk management, analyzing real-world data to detect trends. Ensure mandatory vigilance reporting and execute field corrective actions (RCAs, FSNs) when required to protect patients and market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced manufacturing and supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduce capital equipment, implants, and disposables at scale under ISO 13485 quality systems and FDA 21 CFR part 820 controls to ensure manufacturing consistency and regulatory compliance. Validate processes for sterility and biocompatibility per ISO 11137 and ISO 10993 and maintain full traceability via UDI and lot-level serialization. Optimize inventory to align with OR schedules and implantable device demand using JIT and demand-signal integration with hospital ERP. Manage supplier qualification and continuity through documented audits, dual-sourcing, and corrective action plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercialization and market access focuses on educating surgeons, neurologists and sleep specialists on clinical value through targeted KOL-led programs and hands-on training to drive hospital adoption.\u003c\/p\u003e\n\u003cp\u003eThe team negotiates with hospital procurement, GPOs and payers while supporting reimbursement coding, coverage submissions and evidence dossiers to secure payment pathways.\u003c\/p\u003e\n\u003cp\u003eProduct launches are executed with KOL advocacy, structured training curricula and post-launch outcomes tracking to accelerate uptake and optimize hospital utilization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEducate clinicians via KOL-led training and proctoring\u003c\/li\u003e\n\u003cli\u003eNegotiate with procurement, GPOs and payers\u003c\/li\u003e\n\u003cli\u003eSupport coding, coverage and reimbursement submissions\u003c\/li\u003e\n\u003cli\u003eExecute launches with advocacy, training and outcomes tracking\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer training and service support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProvide in‑theater support for perfusion teams and implants, plus device programming, remote monitoring setup and troubleshooting; deliver CME‑accredited education and certification and sustain installed base through service contracts and upgrades to maximize uptime and clinical outcomes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIn‑theater support\u003c\/li\u003e\n\u003cli\u003eDevice programming \u0026amp; remote monitoring\u003c\/li\u003e\n\u003cli\u003eCME education \u0026amp; certification\u003c\/li\u003e\n\u003cli\u003eService contracts \u0026amp; upgrades\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedtech: heart-lung systems, oxygenators \u0026amp; neuromodulation — \u003cstrong\u003e$1.0B\u003c\/strong\u003e 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign and commercialize heart‑lung systems, oxygenators and neuromodulation devices with quarterly iterations; 2024 revenue ~ $1.0B and pivotal trials (200–800 pts). Maintain ISO 13485 QMS across 10 global sites, FDA\/CE compliance, post‑market surveillance and 21 CFR manufacturing controls. Drive adoption via KOL training, GPO negotiations, reimbursement support, service contracts and in‑theater support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eFY\u003c\/td\u003e\n\u003ctd\u003e~$1.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQMS sites\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal trials\u003c\/td\u003e\n\u003ctd\u003eEnrollment\u003c\/td\u003e\n\u003ctd\u003e200–800 pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual LivaNova Business Model Canvas, not a mockup. It’s the exact file you’ll receive after purchase, with full content and structure intact. Upon payment you’ll get the complete, editable document ready for presentation and editing. No placeholders, no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161593459065,"sku":"livanova-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/livanova-business-model-canvas.png?v=1762695095","url":"https:\/\/portersfiveforce.com\/products\/livanova-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}